

Anthony Mack, CEO of Pathways Neuro Pharma, to Attend the 2024 ACG NY 16th Annual Healthcare Conference

Exploring strategic growth and partnerships in healthcare innovation at New York's premier M&A event.

WEST CHESTER, PENNSYLVANIA, UNITED STATES, June 24, 2024 /EINPresswire.com/ -- [Pathways](#)

“

This conference provides a valuable platform for exploring growth strategies and potential partnerships that align with our mission to advance innovative treatments for neurological disorders.”

Anthony Mack

Neuro Pharma, a leading innovator in gene therapy for neurological disorders, is pleased to announce that CEO Anthony Mack will attend the Association for Corporate Growth (ACG) NY 16th Annual Healthcare Conference. The event is scheduled to take place on June 26, 2024, at The Metropolitan Club of New York, located at 1 East 60th Street, New York, NY 10022.

The ACG conference is a premier event for middle-market M&A dealmakers and business leaders focused on driving growth. Anthony Mack, CEO of Pathways Neuro Pharma, will be engaging with fellow industry leaders during the

one-on-one dealmaking and networking sessions and will participate in the general registration for the healthcare conference open to all attendees.

“I am excited to attend the ACG NY Healthcare Conference and engage with some of the most influential dealmakers and business leaders in the industry,” said Anthony Mack. “This conference provides a valuable platform for exploring growth strategies and potential partnerships that align with Pathways Neuro Pharma’s mission to advance innovative treatments for neurological disorders.”

About Pathways Neuro Pharma

Pathways Neuro Pharma leads the way in innovative treatments for major depressive disorder (MDD) and alcohol use disorder (AUD). We employ a dual strategy of upregulating serotonin and dopamine receptors with existing agonists and pioneering novel gene therapies. Our AAV6.2FF gene therapy platform enhances transgene expression in the brain, providing sustained therapeutic effects for up to 15 months. In the US, 29.5 million people aged 12 and older had

AUD in 2022, and 21 million adults experienced a major depressive episode in 2021.

Our mission focuses on advancing behavioral health through the AAV6.2FF Drug Delivery Platform, designed to mitigate the side effects of serotonin agonist drugs. This platform controls long-term behaviors linked to alcoholism and opioid addiction by boosting transgene expression in the brain.

Pathways Neuro Pharma is committed to revolutionizing behavioral health care, providing safer and more effective treatments for depression, alcoholism, and other neurological disorders.

Warren Lau, General Manager

Pathways Neuro Pharma Inc.

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/722028196>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.